Efficacy of endoscopic ultrasound-guided biliary drainage of malignant biliary obstruction: a systematic review and meta-analysis of randomized controlled trials.
Yousaf Zafar, Hafsa Azam, Muhammad Abdullah Bin Azhar, Fabeeha Shaheen, Syed Sarmad Javaid, Laila Manzoor, Muaaz Masood, Rajesh Krishnamoorthi
{"title":"Efficacy of endoscopic ultrasound-guided biliary drainage of malignant biliary obstruction: a systematic review and meta-analysis of randomized controlled trials.","authors":"Yousaf Zafar, Hafsa Azam, Muhammad Abdullah Bin Azhar, Fabeeha Shaheen, Syed Sarmad Javaid, Laila Manzoor, Muaaz Masood, Rajesh Krishnamoorthi","doi":"10.5946/ce.2024.183","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>Malignant biliary obstruction is a major clinical challenge. We assessed the efficacy of endoscopic ultrasound-guided biliary drainage (EUS-BD) compared with that of endoscopic retrograde cholangiopancreatography biliary drainage (ERCP-BD) or percutaneous transhepatic biliary drainage (PTBD).</p><p><strong>Methods: </strong>We searched for randomized controlled trials comparing EUS-BD with ERCP or PTBD in treating malignant biliary obstruction. Using random-effects models, we synthesized risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs). A subgroup analysis was performed using a comparator (ERCP or PTBD).</p><p><strong>Results: </strong>EUS-BD significantly reduced the risk of stent dysfunction (RR, 0.46; 95% CI, 0.33-0.64), with consistent results in subgroup analysis for ERCP (RR, 0.54; 95% CI, 0.35-0.84) and PTBD (RR, 0.37; 95% CI, 0.22-0.61). It also lowered the risk of post-procedure pancreatitis (RR, 0.24; 95% CI, 0.07-0.83) and reduced tumor ingrowth or overgrowth risk (RR, 0.27; 95% CI, 0.11-0.65), even when compared to ERCP alone (RR, 0.28; 95% CI, 0.11-0.70). EUS-BD demonstrated a lower risk of adverse events compared to PTBD (RR, 0.37; 95% CI, 0.14-0.97) and reduced length of hospital stay (WMD, -1.03; 95% CI, -1.53 to -0.53) when compared to ERCP.</p><p><strong>Conclusions: </strong>EUS-BD outperformed ERCP-BD and PTBD in reducing stent dysfunction, postprocedural pancreatitis, and tumor ingrowth or overgrowth.</p>","PeriodicalId":10351,"journal":{"name":"Clinical Endoscopy","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5946/ce.2024.183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aims: Malignant biliary obstruction is a major clinical challenge. We assessed the efficacy of endoscopic ultrasound-guided biliary drainage (EUS-BD) compared with that of endoscopic retrograde cholangiopancreatography biliary drainage (ERCP-BD) or percutaneous transhepatic biliary drainage (PTBD).
Methods: We searched for randomized controlled trials comparing EUS-BD with ERCP or PTBD in treating malignant biliary obstruction. Using random-effects models, we synthesized risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs). A subgroup analysis was performed using a comparator (ERCP or PTBD).
Results: EUS-BD significantly reduced the risk of stent dysfunction (RR, 0.46; 95% CI, 0.33-0.64), with consistent results in subgroup analysis for ERCP (RR, 0.54; 95% CI, 0.35-0.84) and PTBD (RR, 0.37; 95% CI, 0.22-0.61). It also lowered the risk of post-procedure pancreatitis (RR, 0.24; 95% CI, 0.07-0.83) and reduced tumor ingrowth or overgrowth risk (RR, 0.27; 95% CI, 0.11-0.65), even when compared to ERCP alone (RR, 0.28; 95% CI, 0.11-0.70). EUS-BD demonstrated a lower risk of adverse events compared to PTBD (RR, 0.37; 95% CI, 0.14-0.97) and reduced length of hospital stay (WMD, -1.03; 95% CI, -1.53 to -0.53) when compared to ERCP.
Conclusions: EUS-BD outperformed ERCP-BD and PTBD in reducing stent dysfunction, postprocedural pancreatitis, and tumor ingrowth or overgrowth.